Auauniversity

Presented by Kelly Stratton, MD and Alicia Morgans, MD This educational activity is supported by independent educational grants from: AbbVie Astellas AstraZeneca Bayer HealthCare Pharmaceuticals Inc. Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck Pfizer, Inc. CME Available: https://auau.auanet.org/node/30123

Case-Based Discussion: BCR and mHSPC and M0 CRPC Presented by Stephen Boorjian, MD and Michael Cookson, MD This educational activity is supported by independent educational grants from: AbbVie Astellas AstraZeneca Bayer HealthCare Pharmaceuticals Inc. Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck Pfizer, Inc. CME Available: https://auau.auanet.org/node/30122

At the conclusion of this activity, participants will be able to: 1. Identify the role of genetic testing in men with advanced, metastatic and CRPC. 2. State the criteria for genetic testing of prostate cancer patients, the gene panels available, and options for testing these men. 3. Describe results of genetic testing and relay this information to patients in order to facilitate shared-decision making based on the test results. 4. Explain the importance of testing for germline mutations and their implication for novel therapies such as PARP inhibitors. This educational series is supported by independent educational grants from: Astellas AstraZeneca Bristol Myers Squibb Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck Pfizer, Inc Sanofi Genzyme UroGen Pharma, Inc.

At the conclusion of this activity, participants will be able to: 1. Examine racial and geographic disparities in in prostate cancer and prostate cancer care. 2. Identify important causes for disparities as well as possible remedies to address these causes. This educational series is supported by independent educational grants from: Astellas AstraZeneca Bristol Myers Squibb Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck Pfizer, Inc Sanofi Genzyme UroGen Pharma, Inc.

At the conclusion of this activity, participants will be able to: 1. Identify new technologies for the treatment of urothelial carcinoma and analyze the risks and benefits of treatment. 2. Facilitate discussions with patients and caregivers regarding of urothelial carcinoma treatment options. This educational series is supported by independent educational grants from: Astellas AstraZeneca Bristol Myers Squibb Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck Pfizer, Inc Sanofi Genzyme UroGen Pharma, Inc. CME Available: https://auau.auanet.org/node/29841

At the conclusion of this activity, participants will be able to: 1. Review the evidence and outcomes on the treatment of M1 HSPC, MO CRPC and M1 CRPC as outlined in the newly updated AUA Advanced, Metastatic and CRPC guidelines. 2. Improve diagnostic and therapeutic decision-making processes by illustrating the application of these guidelines in urological practice This educational series is supported by independent educational grants from: • Astellas • AstraZeneca • Bristol Myers Squibb • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC • Merck • Pfizer, Inc • Sanofi Genzyme • UroGen Pharma, Inc. CME Available: https://auau.auanet.org/node/30174

At the conclusion of this activity, participants will be able to: 1. Describe new and emerging targeted for patients with locally-advanced and advanced kidney cancer and the role of adjuvant therapy. 2. Review the mechanisms of action, efficacy, and safety of currently available targeted treatment of RCC. 3. Facilitate discussions with patients and caregivers regarding RCC treatment options. This educational series is supported by independent educational grants from: Astellas AstraZeneca Bristol Myers Squibb Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck Pfizer, Inc Sanofi Genzyme UroGen Pharma, Inc. CME Available: https://auau.auanet.org/node/29851

Immune Checkpoint Inhibitors in RCC At the conclusion of this activity, participants will be able to: 1. Discuss the current immunotherapy options available for the treatment of RCC. 2. Describe both completed and accruing clinical trials that are defining the paradigms of immunotherapy use in RCC. 3. Identify and manage immune related adverse events. This educational series is supported by independent educational grants from: Astellas AstraZeneca Bristol Myers Squibb Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck Pfizer, Inc Sanofi Genzyme UroGen Pharma, Inc. CME Available: https://auau.auanet.org/node/29846

The Expanding Role of Immune Checkpoint Inhibitors in MIBC and NMIBC At the conclusion of this activity, participants will be able to: 1. Recognize both historic and newer immunotherapy options in the treatment of bladder cancer. 2. Describe the mechanism of action of immunotherapy regimens. 3. Identify and manage the adverse events related to these agents. This educational series is supported by independent educational grants from: Astellas AstraZeneca Bristol Myers Squibb Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck Pfizer, Inc Sanofi Genzyme UroGen Pharma, Inc. CME Available: https://auau.auanet.org/node/29831

Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline Podcast: Part 1 At the conclusion of this activity, participants will be able to: 1. Analyze breakthrough treatments in the management of advanced and metastatic hormone sensitive prostate cancer (mHSPC) and castration resistant prostate cancer (CRPC). 2. Identify the active agents and their mechanism of action in the management of mHSPC, nmCRPC and mCRPC. 3. Describe the indications, sequencing and combinations for treatment with approved agents in the management of mHSPC and nmCRPC. This educational series is supported by independent educational grants from: Astellas AstraZeneca Bristol Myers Squibb Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck Pfizer, Inc Sanofi Genzyme UroGen Pharma, Inc. CME Available: https://auau.auanet.org/node/29816

Course Description: The course is centered on reviewing medical management and prevention of kidney stones. A focus is on the AUA guidelines for the medical management of stones. The course is focused on practical information, for example, how to interpret 24 hour urines, when to prescribe medication. It also has a focus on dietary management for stones. Learning Objectives: Upon completion of this activity, participants will be able to: 1. Interpret a 24 hour urine collection and identify underlying metabolic causes for recurrent stone disease. 2. Prescribe appropriate medical treatment for the prevention of kidney stones based on findings on a 24 hour urine collection. 3. Prescribe targeted dietary changes for underlying metabolic abnormalities on 24 hour urine testing such as hypercalciuria, hyperoxaluria, and hypocitraturia.

Course Description: The diagnosis and management of Male Lower Urinary Tract Symptoms (mLUTS) and benign prostatic hyperplasia (BPH) has evolved dramatically over the past 5 years with changing algorithms. The AUA BPH Guidelines were revised in 2018 focusing primarily on diagnostic algorithms and surgical modalities. The 2020 Guidelines will incorporate recommendations about medical therapies. This course is designed to review, discuss and develop a coherent diagnostic and treatment strategy for men with mLUTS. This will include risk factors such as obesity, the role of both AUA and international guidelines, established algorithms, medical therapy with both mono and combination therapy with agents such as alpha blockers, antimuscarinics, beta - 3 agonists, 5-alpha reductase inhibitors, PDE - 5 inhibitors and surgical options including minimally invasive (UroLift / Rezum) and surgical options (electrosurgical, laser, aquablation). In addition, how these agents dovetail with sexual function and testosterone rep

This educational series is supported by an independent educational grant from: AstraZeneca; Merck; Pfizer Inc. CME Available: https://auau.auanet.org/node/29200 Course Description: Over the last several years, there has been a dramatic increase in our understanding of the role of genetic testing in prostate cancer. Urologists are suddenly being confronted with new information surrounding screening guidelines for men at high genetic risk of prostate cancer, genetic testing in men with both localized and metastatic prostate cancer, and the impact on treatment decisions in men with prostate cancer and inherited DNA damage repair gene mutations. To increase urologists understanding related to the newest treatment options for prostate cancer, the featured 60-minute panel discussion led by experts in their field, will explore how to translate the latest scientific advances into routine clinical practice, improving the care of patients who are at a markedly-elevated risk of progressions and death from prostate can

Join Drs. Brian Matlaga and Ryan Hsi as they share insights into diagnostics, therapeutic options, and treatment outcomes for urinary stone disease. Host: Brian Matlaga, MD, MPH, Johns Hopkins University School of Medicine Guest: Ryan Hsi, MD, Vanderbilt University This project has been funded in whole or in part with Federal funds from the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N94019F00260.

Course Description: This course tackles key controversies in surgical stone disease and elucidates the most current rationale to varying treatments using a case-based scenarios. Two well-known senior experts give honest and clear assessments of the field in these controversial areas. Active discussion is encouraged, and the discussion favors more experienced endourologists. Controversies include: dusting vs basketing, mini PCNL vs. standard PCNL, supine vs prone PCNL, micro PCNL vs ureteroscopy, wireless vs safety wire ureteroscopy, stents vs no stents, SWL vs URS and retrograde vs. antegrade caliceal diverticular stone treatments. Learning Objectives Upon completion of this activity, participants will be able to: 1. Apply standard therapy to complex problems. 2. Counsel patients and colleagues regarding controversial topics in stone management. 3. Manage all aspects of a complex surgical stone case.

This course will assist Urologists and Allied staff in understanding the evidence-base and the clinical role of the newly-introduced techniques for treating BPH and LUTs. The technology behind each will be reviewed and the quality of the data supporting each will be examined with emphasis placed on the Pivotal trials and their methodology. The current Guidelines will be reviewed and a practical discussion of the peri-operative considerations and tips and tricks for the use of each will be covered. Upon completion of this activity, participants will be able to: 1. Differentiate between each of the new technologies for treating BPH/LUTS both based on mode-of-action and the quality of supporting evidence. 2. Describe the features expected of a Pivotal Trial for BPH Medical Devices and be able to compare and contrast the findings of these trials for each of the current devices. 3. Discuss the evidence base for current technologies, including pivotal studies, and be able to define the role and clinical expectati

This course will review the new AUA guidelines on premature ejaculation and delayed ejaculation. The course will provide a clinical framework for the diagnosis, evaluation, treatment and follow-up of patients with ejaculation disorders based on the best available published literature. The course will review correct application of the new AUA guidelines in clinical practice. This course will be a benefit to practicing urologists, primary care providers, other non-physician providers, residents preparing for their certification exam and physicians preparing for their re-certification exam. Upon completion of this activity, participants will be able to: 1. Analyze the latest evidence on the management of disorders of ejaculation as outlined in the AUA guidelines. 2. Recognize the role of mental health professionals in managing disorders of ejaculation. 3. Improve the diagnostic and therapeutic decision making processes by understanding the evidence basis of these guidelines in urological practice. 4. Acquire

This course will address the timely and accurate diagnosis of testicular cancer and emphasize the appropriate integration of pathologic, radiographic and serologic variables in assessing individual patient's risk in both low and high-stage germ cell tumors (GCT). Important features regarding the natural history of GCTs will also be emphasized. Patient selection and treatment options for patients with clinical stage I non-seminomatous germ cell tumors (NSGCT) such as surveillance, 1° retroperitoneal lymph node dissection (RPLND) and chemotherapy will be discussed. Upon completion of this activity, course participants will be able to: 1. Cite current concepts and controversies in the management of low-stage and high-stage nonseminomatous germ cell tumors (NSGCTs). 2. Discuss current concepts and controversies in the management of low-stage and high-stage seminoma. 3. Describe the biology and clinical implications of teratoma. 4. Illustrate importance of tumor markers and their role in diagnosis, follow up and

This interactive webinar will answer questions medical students have regarding facilitation of remote exposure to urology training programs, and the resources available to support urologic education for medical students. Our panel consists of members of the Society of Academic Urologists who will share their insights to help you navigate remote urologic training

This course will focus on what general urologists who have not had fellowship or specialty training in male infertility can do to evaluate and treat male reproductive disorders. Basic science presented will be limited to that which is absolutely essential to understand the basic evaluation and treatment. In 90% of male infertility cases, a good history and careful physical examination, along with a basic semen analysis, which can often be performed by the doctor himself, will allow the general urologist to come up with a tentative diagnosis and treatment plan. More advanced testing is primarily designed to confirm the diagnosis. Key points of history, including inheritance issues, will be discussed. The finer points of physical examination, which in male infertility, due to the ready accessibility of the male reproductive organs to physical examination of a relaxed scrotum, allows the diagnosis to be made without the necessity for imaging studies in the majority of men. Interpretation of semen analysis will b